Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Barchart · 1d ago

One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts

Deep and durable ongoing responses with median time on treatment of 15 months

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.